Actuate Therapeutics' Quiet Period Will End on September 23rd (NASDAQ:ACTU)

Actuate Therapeutics' (NASDAQ:ACTU - Get Free Report) quiet period is set to expire on Monday, September 23rd. Actuate Therapeutics had issued 2,800,000 shares in its initial public offering on August 13th. The total size of the offering was $22,400,000 based on an initial share price of $8.00. During Actuate Therapeutics' quiet period, insiders and underwriters involved in the IPO are prevented from issuing any earnings forecasts or research reports for the company because of regulations issued by the Securities and Exchange Commission. Following the expiration of the company's quiet period, it's expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

Actuate Therapeutics Trading Up 4.5 %

Actuate Therapeutics stock traded up $0.36 during midday trading on Monday, hitting $8.37. The stock had a trading volume of 25,421 shares, compared to its average volume of 40,551. The firm has a market capitalization of $159.95 million and a price-to-earnings ratio of 53.40. Actuate Therapeutics has a 52-week low of $7.33 and a 52-week high of $10.16.

Insider Activity at Actuate Therapeutics

In other news, major shareholder Leslie W. Kreis sold 24,999 shares of the firm's stock in a transaction dated Wednesday, August 14th. The stock was sold at an average price of $9.00, for a total transaction of $224,991.00. Following the completion of the transaction, the insider now owns 131,248 shares in the company, valued at $1,181,232. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In other news, major shareholder Leslie W. Kreis sold 24,999 shares of the business's stock in a transaction dated Wednesday, August 14th. The shares were sold at an average price of $9.00, for a total value of $224,991.00. Following the sale, the insider now directly owns 131,248 shares in the company, valued at approximately $1,181,232. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Equity Cof Lp Bios acquired 500,000 shares of Actuate Therapeutics stock in a transaction on Wednesday, August 14th. The shares were bought at an average cost of $8.00 per share, for a total transaction of $4,000,000.00. Following the completion of the purchase, the director now directly owns 1,259,427 shares of the company's stock, valued at $10,075,416. The disclosure for this purchase can be found here. 19.90% of the stock is owned by corporate insiders.

About Actuate Therapeutics

Actuate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer.